US20150329482A1 - Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid - Google Patents

Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid Download PDF

Info

Publication number
US20150329482A1
US20150329482A1 US14/810,783 US201514810783A US2015329482A1 US 20150329482 A1 US20150329482 A1 US 20150329482A1 US 201514810783 A US201514810783 A US 201514810783A US 2015329482 A1 US2015329482 A1 US 2015329482A1
Authority
US
United States
Prior art keywords
methyl
acid
ethyl
sulphamoyl
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/810,783
Inventor
Tom Cornelis Hortense Govaerts
Jean-Pierre-Andre Marc Bongartz
Patrick Hubert J. Nieste
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Priority to US14/810,783 priority Critical patent/US20150329482A1/en
Publication of US20150329482A1 publication Critical patent/US20150329482A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04Diamides of sulfuric acids
    • C07C307/06Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Definitions

  • the present invention relates to an improved method for the preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2- ⁇ 2-[methyl-(sulphamoyl)-amino]-ethoxy ⁇ -ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid.
  • the present invention also relates to a new compound, namely tent-butyl (methyl- ⁇ 2-[2-(methylamino)-ethoxy]-ethyl ⁇ -sulphamoyl)-carbamate, used in this improved method.
  • WO 2010 / 003658 describes some macrocyclic indoles that can be used as inhibitors of the hepatitis C virus.
  • the aim of the present invention is to provide an improved method for the synthesis of 13-cyclohexyl-3-methoxy-6-[methyl-(2- ⁇ 2-[methyl-(sulphamoyl)-amino]-ethoxy ⁇ -ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid (Compound ‘A’) that is easier to carry out and is more efficient than the method known so far.
  • the present invention achieves this aim by providing an improved method for the preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2- ⁇ 2-[methyl-(sulphamoyl)-amino]-ethoxy ⁇ -ethyl)-carbamoyl]-7H-indolo-[2, 1 -a]-[2]-benzazepine- 10-carboxylic acid (‘Compound A’), characterized in that it comprises the following steps:
  • the coupling agent in Step a) is e.g. carbodiimidazole (CDI), dicyclohexylcarbodiimide (DCC), O-(7-azabenztriazolo-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), bromotri-(pyrrolidino)-phosphonium hexafluorophosphate (PyBrOP), a combination of 1-hydroxybenztriazole hydrate (HOBt.H 2 O) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDCI).
  • CDI carbodiimidazole
  • DCC dicyclohexylcarbodiimide
  • HATU O-(7-azabenztriazolo-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
  • PyBrOP bromotri-
  • a suitable solvent in Step a) is e.g. dichloromethane, 2-methyltetrahydrofuran, acetonitrile, acetone, 2-butanone, 4-methyl-2-pentanone, ethyl acetate, isopropyl acetate or toluene.
  • the hydrolysis in Step b) can be carried out by using trifluoroacetic acid, methanesulphonic acid, hydrogen chloride, hydrogen bromide, para-toluenesulphonic acid, sulphuric acid or phosphoric acid.
  • Steps a) and b) can be carried out as a two-step synthesis, in which Compound (II) is isolated in Step a) before carrying out Step b), or else Steps a) and b) are conducted as a one-vessel synthesis.
  • the overall yield obtained in Steps a) and b) is between 86 and 91%, depending on which of the procedures described in Examples 3, 4 and 5 (Experiment B) is used to carry out the new method.
  • the present invention also relates to a new compound (Compound ‘B’) with the following formula, and possible acid-addition salts thereof:
  • the acid-addition salts of Compound ‘B’ include the salts that Compound ‘B’ can form with organic or inorganic acids, such as mineral acids, sulphonic acids, carboxylic acids and phosphorus-containing acids.
  • organic or inorganic acids such as mineral acids, sulphonic acids, carboxylic acids and phosphorus-containing acids.
  • salt-forming mineral acids are hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid, sulphuric acid, nitric acid, chloric acid, perchloric acid and phosphoric acid.
  • Salt-forming sulphonic acids are toluenesulphonic acid, benzenesulphonic acid, methanesulphonic acid and trifluormethanesulphonic acid.
  • Salt-forming carboxylic acids are formic acid, acetic acid, propionic acid, butanoic acid and the like.
  • Salt-forming dicarboxylic acids are oxalic acid, malonic acid, succinic acid, glutaric acid and the like.
  • Salt-forming hydroxy-acids are glycollic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid and the like.
  • Other salt-forming carboxylic acids are trifluoroacetic acid, benzoic acid, chloroacetic acid, phthalic acid, maleic acid and malonic acid.
  • Phosphorus-containing acids are various phosphono-acids, phosphonic acids and phosphinic acids.
  • This new Compound ‘B’ can be synthesized as follows:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The present invention relates to an improved method for the preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid. The present invention also relates to a new compound, namely tent-butyl (methyl-{2-[2-(methylamino)-ethoxy]-ethyl}-sulphamoyl)-carbamate, used in this improved method.

Description

  • The present invention relates to an improved method for the preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid. The present invention also relates to a new compound, namely tent-butyl (methyl-{2-[2-(methylamino)-ethoxy]-ethyl}-sulphamoyl)-carbamate, used in this improved method.
  • Figure US20150329482A1-20151119-C00001
  • Figure US20150329482A1-20151119-C00002
  • WO 2010 / 003658 describes some macrocyclic indoles that can be used as inhibitors of the hepatitis C virus. The synthesis of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1 -a]-[2]-benzazepine-10-carboxylic acid (Compound ‘A’) was described there on pages 38 and 39 (see Compound 1e) as a three-step synthesis, giving an overall yield of 62%.
  • Figure US20150329482A1-20151119-C00003
    Figure US20150329482A1-20151119-C00004
    Figure US20150329482A1-20151119-C00005
  • The aim of the present invention is to provide an improved method for the synthesis of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid (Compound ‘A’) that is easier to carry out and is more efficient than the method known so far.
  • The present invention achieves this aim by providing an improved method for the preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2, 1 -a]-[2]-benzazepine- 10-carboxylic acid (‘Compound A’), characterized in that it comprises the following steps:
    • a) 1 0-(tert-butoxycarbonyl)-13-cyclohexyl-3-methoxy-7H-indolo-[2,1 -a]-[2]-benzazepine-6-carboxylic acid (Compound I) is reacted with tent-butyl (methyl-{2-[2-(methylamino)-ethoxy]-ethyl}-sulphamoyl)-carbamate (‘Compound B’) in the presence of a coupling agent in a suitable solvent
  • Figure US20150329482A1-20151119-C00006
    • b) and Compound (II) thus obtained is hydrolysed with an acid to prepare Compound ‘A’.
  • Figure US20150329482A1-20151119-C00007
  • The coupling agent in Step a) is e.g. carbodiimidazole (CDI), dicyclohexylcarbodiimide (DCC), O-(7-azabenztriazolo-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), bromotri-(pyrrolidino)-phosphonium hexafluorophosphate (PyBrOP), a combination of 1-hydroxybenztriazole hydrate (HOBt.H2O) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDCI).
  • A suitable solvent in Step a) is e.g. dichloromethane, 2-methyltetrahydrofuran, acetonitrile, acetone, 2-butanone, 4-methyl-2-pentanone, ethyl acetate, isopropyl acetate or toluene.
  • The hydrolysis in Step b) can be carried out by using trifluoroacetic acid, methanesulphonic acid, hydrogen chloride, hydrogen bromide, para-toluenesulphonic acid, sulphuric acid or phosphoric acid.
  • Steps a) and b) can be carried out as a two-step synthesis, in which Compound (II) is isolated in Step a) before carrying out Step b), or else Steps a) and b) are conducted as a one-vessel synthesis.
  • The overall yield obtained in Steps a) and b) is between 86 and 91%, depending on which of the procedures described in Examples 3, 4 and 5 (Experiment B) is used to carry out the new method.
  • The present invention also relates to a new compound (Compound ‘B’) with the following formula, and possible acid-addition salts thereof:
  • Figure US20150329482A1-20151119-C00008
  • tert-Butyl-(methyl-{2-[2-(methylamino)-ethoxy]-ethyl}-sulphamoyl)-carbamate (Compound ‘B’)
  • The acid-addition salts of Compound ‘B’ include the salts that Compound ‘B’ can form with organic or inorganic acids, such as mineral acids, sulphonic acids, carboxylic acids and phosphorus-containing acids. Examples of salt-forming mineral acids are hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid, sulphuric acid, nitric acid, chloric acid, perchloric acid and phosphoric acid. Salt-forming sulphonic acids are toluenesulphonic acid, benzenesulphonic acid, methanesulphonic acid and trifluormethanesulphonic acid. Salt-forming carboxylic acids are formic acid, acetic acid, propionic acid, butanoic acid and the like. Salt-forming dicarboxylic acids are oxalic acid, malonic acid, succinic acid, glutaric acid and the like. Salt-forming hydroxy-acids are glycollic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid and the like. Other salt-forming carboxylic acids are trifluoroacetic acid, benzoic acid, chloroacetic acid, phthalic acid, maleic acid and malonic acid. Phosphorus-containing acids are various phosphono-acids, phosphonic acids and phosphinic acids.
  • This new Compound ‘B’ can be synthesized as follows:
  • Figure US20150329482A1-20151119-C00009
  • EXPERIMENTAL
  • The following abbreviations are used here:
    • A/A: active yield
    • CDI: carbonyldiimidazole
    • CSI: chlorosulphonyl isocyanate
    • DBU: 1,8-diaza-bicyclo-[5,4,0]-undecene-7
    • DIPE: diisopropyl ether
    • DMAP: 4-dimethylaminopyridine
    • DME: 1,2-dimethoxyethane
    • DMSO-d6: deuterated dimethylsulphoxide
    • EDCI: 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride
    • F/F: physical yield
  • HOBt: 1-hydroxybenzotriazole hydrate
    • iPrOAc: isopropyl acetate
    • LC: liquid chromatography
    • MeCN: acetonitrile
    • MEK: methyl ethyl ketone (2-butanone)
  • MeTHF: 2-methyltetrahydrofuran
    • MeSO3H: methanesulphonic acid
    • MIK: methyl isopropyl ketone
    • MTBE: methyl tent-butyl ether
    • NMR: nuclear magnetic resonance
    • tBuOH: tent-butanol
    • tBOC: tert-butoxycarbonyl
    • THF: tetrahydrofuran
    EXAMPLE 1
  • Figure US20150329482A1-20151119-C00010
  • A solution of 8.205 g of chlorosulphonyl isocyanate (58.0 mmol, 1 Eq) in 50 ml of acetonitrile (1 litre/mol) was cooled to −2° C. on an ice/salt bath under nitrogen, using a 500-ml four-neck flask fitted with a thermometer, a magnetic stirrer and a dropping (addition) funnel. A solution of 4.297 g of tent-butanol (58.0 mmol, 1 Eq) in 33 ml of acetonitrile (0.5 l/mol) was added dropwise over 20 minutes, with the temperature remaining below 4° C. Four minutes later (when the temperature had dropped to 1° C.), a solution of DMAP (116.0 mmol, 2 Eq) in 55 ml of acetonitrile (1 litre/mol) was added dropwise over 24 minutes, with the temperature remaining below 5° C.
  • The solution was allowed to stand for 65 minutes to ensure the best crystallization, with the temperature remaining below 3° C. The white suspension was filtered on a Buchner funnel filter, giving a non-tacky white powder. The precipitate was dried overnight in a drying cabinet at 40° C. under vacuum, which gave 9.465 g of Intermediate (I).
  • EXAMPLE 2
  • Figure US20150329482A1-20151119-C00011
  • 109.1 g (0.825 mol) of 1,5-bis-(methylamino)-3-oxapentane and 1.5 litres of acetonitrile were introduced into a reaction vessel with an inert atmosphere. The resulting solution was cooled to 0° C., and 226 g (0.75 mol) of Intermediate (1) was added to it. The mixture thus obtained was stirred first for 6 hours at 10° C., and then for 3 days at 0° C. The precipitate was filtered off and washed with acetonitrile. After drying at 25° C., Compound ‘B’ was obtained in a yield of 95 g (40.6%, corrected for purity) in the form of white crystals.
  • EXAMPLE 3
  • Figure US20150329482A1-20151119-C00012
  • 0.400 g (0.82 mmol, 1 Eq) of 10-(tert-butoxycarbonyl)-13-cyclohexyl-3-methoxy- 7H-indolo-[2,1-a]-[2]-benzazepine-6-carboxylic acid (called Compound 1b on page 38 of WO 2010/003658), 0.164 g of HOBt (1.07 mmol, 1.3 Eq) and 0.201 g of EDCI (1.07 mmol, 1.3 Eq) were dissolved in 6.5 ml of MeTHF (8 l/mol) in a closed glass flask. The contents of the flask were stirred for 1 hour at room temperature. 0.469 g of Compound ‘B’ (64.3 wt-%, 0.98 mmol, 1.2 Eq) was then added to the reaction mixture, which was analysed after a reaction time of 18 hours. Analysis by LC indicated that Intermediate (2) had been obtained in a yield of 93.1%.
  • EXAMPLE 4
  • Figure US20150329482A1-20151119-C00013
  • 12.00 g (24.61 mmol, 1 Eq) of 10-(tert-butoxycarbonyl)-13-cyclohexyl-3-methoxy- 7H-indolo-[2,1-a]-[2]-benzazepine-6-carboxylic acid, 4.92 g of HOBt (31.99 mmol, 1.3 Eq) and 6.03 g of EDCI (31.99 mmol, 1.3 Eq) were introduced into a 100-ml flask and dissolved in 200 ml of MeTHF (8 l/mol). The contents of the flask were stirred for 1 hour at room temperature. Then 11.663 g of Compound ‘B’ (77.4 wt-%, 29.53 mmol, 1.2 Eq) was added, and the reaction mixture was analysed after a reaction time of 18 hours. Analysis by LC indicated that Intermediate (2) had been obtained in a yield of 98.3%.
  • The reaction mixture was then extracted and washed first with two 180-ml portions of H2O (15 l/mol), and then with two 180-ml portions of an NaHCO3 solution (15 l/mol). The organic layer was dried with 2.4 g of Na2SO4 and filtered, after which the volume of the filtrate obtained was determined. 60 ml of MeTHF was added to make up the volume to 200 ml (8 l/M). Analysis by LC indicated that Intermediate (2) had been obtained in a yield of 93.7%.
  • EXAMPLE 5
  • Figure US20150329482A1-20151119-C00014
  • Experiment A
  • To 13.722 g of Intermediate (2) (16.4 wt-%, 1 Eq, 2.88 mmol) dissolved in MeTHF (8 l/mol) in a 100-ml flask without a nitrogen atmosphere(this solution contained 2.17 wt-% of water), 251 pl of water was added to bring the water content up to 4 wt-%. After the addition of 1.9 ml of MeSO3H (1 Eq, 28.8 mmol), the reaction mixture was placed on an oil bath heated to 50° C. A sample was taken and analysed after a reaction time of 5 hours. After a reaction time of 22 hours, the reaction mixture was brought to room temperature, and sampled again for analysis. The whole reaction mixture weighed 15.022 g.
  • Analysis by LC
    • After 5 hours: 90.1% of Compound ‘A’
    • After 22 hours: 75.4% of Compound ‘A’
    Experiment B
  • 119.6 g of Intermediate (2) (10.27 wt-%, 15.7 mmol, 1 Eq) was dissolved in MeTHF (8 l/mol) in a reaction vessel with a nitrogen atmosphere. The solution contained 2.21 wt-% of water. 2.81 g of water were added to bring the water content up to 4 wt-%. After the addition of 10.31 ml of MeSO3H (157 mmol, 10 Eq), the reaction mixture was heated to 50° C. After a reaction time of 5 hours, the reaction mixture was cooled to room temperature, and a sample of it was analysed. The whole reaction mixture weighed 119.6 g.
  • Analysis by LC
    • 92.7% of Compound ‘A’

Claims (2)

1.-7. (canceled)
8. tert-Butyl (methyl-{2-[2-(methylamino)-ethoxy]-ethyl}-sulphamoyl)-carbamate, and acid-addition salts thereof.
Figure US20150329482A1-20151119-C00015
US14/810,783 2010-06-24 2015-07-28 Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid Abandoned US20150329482A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/810,783 US20150329482A1 (en) 2010-06-24 2015-07-28 Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10167221 2010-06-24
US13/805,607 US9127010B2 (en) 2010-06-24 2011-06-24 Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid
PCT/EP2011/060606 WO2011161232A1 (en) 2010-06-24 2011-06-24 PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
US14/810,783 US20150329482A1 (en) 2010-06-24 2015-07-28 Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US13/806,607 Division US20130091758A1 (en) 2010-06-24 2011-06-22 Insect bait
PCT/EP2011/060606 Division WO2011161232A1 (en) 2010-06-24 2011-06-24 PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID

Publications (1)

Publication Number Publication Date
US20150329482A1 true US20150329482A1 (en) 2015-11-19

Family

ID=43216626

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/805,607 Expired - Fee Related US9127010B2 (en) 2010-06-24 2011-06-24 Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid
US14/810,783 Abandoned US20150329482A1 (en) 2010-06-24 2015-07-28 Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/805,607 Expired - Fee Related US9127010B2 (en) 2010-06-24 2011-06-24 Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid

Country Status (11)

Country Link
US (2) US9127010B2 (en)
EP (1) EP2585438B1 (en)
JP (1) JP5870098B2 (en)
CN (1) CN103097356B (en)
AU (1) AU2011268922B2 (en)
BR (1) BR112012032889A2 (en)
CA (1) CA2801517C (en)
IL (1) IL223427A (en)
MX (1) MX2012015198A (en)
RU (1) RU2559886C2 (en)
WO (1) WO2011161232A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9427440B2 (en) 2008-07-08 2016-08-30 Janssen Sciences Ireland Uc Macrocyclic indole derivatives useful as hepatitis C virus inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105473A1 (en) * 2008-07-08 2011-05-05 Tibotec Pharmaceuticals Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CZ298463B6 (en) 1996-04-23 2007-10-10 Vertex Pharmaceuticals Incorporated Urea derivatives intended for use as IMPDH enzyme inhibitors and pharmaceutical compositions in which the derivatives are comprised
DK0966465T3 (en) 1997-03-14 2003-10-20 Vertex Pharma Inhibitors of IMPDH enzymes
ES2405316T3 (en) 1999-03-19 2013-05-30 Vertex Pharmaceuticals Incorporated IMPDH enzyme inhibitors
WO2002019369A1 (en) 2000-08-30 2002-03-07 Matsushita Electric Industrial Co., Ltd. Plasma display unit and production method thereof
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
KR20080040032A (en) 2005-09-02 2008-05-07 티보텍 파마슈티칼즈 리미티드 Benzodiazepines as hcv inhibitors
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) * 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8101595B2 (en) 2006-12-20 2012-01-24 Istituto di Ricerche di Biologia Molecolare P. Angletti SpA Antiviral indoles
AU2008277440A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105473A1 (en) * 2008-07-08 2011-05-05 Tibotec Pharmaceuticals Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PubChem (see CID 56592562, “SCHEMBL12070859”, p. 1-11, downloaded on 1/31/2017 from <https://pubchem.ncbi.nlm.nih.gov/compound/56592562> with a public availability date of 1/30/2012). *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9427440B2 (en) 2008-07-08 2016-08-30 Janssen Sciences Ireland Uc Macrocyclic indole derivatives useful as hepatitis C virus inhibitors

Also Published As

Publication number Publication date
BR112012032889A2 (en) 2015-09-15
EP2585438B1 (en) 2014-08-20
MX2012015198A (en) 2013-02-11
US20130102777A1 (en) 2013-04-25
WO2011161232A1 (en) 2011-12-29
RU2013103004A (en) 2014-07-27
JP2013530976A (en) 2013-08-01
AU2011268922A1 (en) 2013-01-10
CN103097356B (en) 2016-01-13
RU2559886C2 (en) 2015-08-20
US9127010B2 (en) 2015-09-08
CA2801517C (en) 2017-12-12
CN103097356A (en) 2013-05-08
IL223427A (en) 2015-04-30
CA2801517A1 (en) 2011-12-29
JP5870098B2 (en) 2016-02-24
AU2011268922B2 (en) 2014-06-12
EP2585438A1 (en) 2013-05-01

Similar Documents

Publication Publication Date Title
US8754225B2 (en) Process for preparing a biphenyl-2-ylcarbamic acid
ES2769255T3 (en) Methods for making protein deacetylase inhibitors
SG188996A1 (en) Methods and compositions for treatment of diabetes and dyslipidemia
US20080114171A1 (en) Solifenacin base forms and preparation thereof
US20150329482A1 (en) Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid
CN109641901B (en) Abamebactam free acid
US7601832B2 (en) Process for making aztreonam
EP3498695B1 (en) Method for synthesizing 3-(difluoromethyl)-1-methyl-1h-pyrazole-4-carboxylic acid
ES2656820T3 (en) Process for preparing biphenylimidazole compounds
US20090170948A1 (en) Crystal forms of O-desmethylvenlafaxine fumarate
CN105683186A (en) An industrially applicable process for preparing high purity aclidinium bromide
JP6787331B2 (en) Method for producing acid halide solution, mixed solution, and method for producing monoester compound
KR20010015866A (en) Process for producing toluene derivatives
JP2009518380A (en) Preparation of 2-chloroethoxy-acetic acid-N, N-dimethylamide
KR100663167B1 (en) Process for preparing itopride hydrochloride
EP2328884A2 (en) A process for the preparation of strontium ranelate
TW200804269A (en) Chemical process
US20140121267A1 (en) Methods and compositions for treatment of diabetes and dyslipidemia
JP7380555B2 (en) Manufacturing method of polymerizable compound
US7923571B2 (en) Process for preparing substituted 2-alkoxycarbonyl-3-aminothiophenes
KR101800923B1 (en) Production method for 4-carbonyl oxyquinoline derivative
KR20060065583A (en) Processes for preparing (2s)-3-(4-(2-[amino]-2-oxoethoxy)phenyl)-2-ethoxypropanoic acid derivatives
KR101409554B1 (en) Crystal forms of o-desmethylvenlafaxine fumarate
JP2005232114A (en) N-cinnamoyl-benzene sulfonamide derivative and plant disease preventing and controlling agent for agriculture and horticulture
WO2002055494A1 (en) Process for preparation of cyclic amine derivatives

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE